Premium
Promoters and investors in Aragen Life Sciences, the Goldman Sachs-backed contract research organisation (CRO), plan to sell a 10% stake in a pre-IPO round, valuing the company at Rs 10,000-12,000 crore ($1.5 billion), a media report said. Potential investors, including Quadria Capital and Denmark-based pharmaceutical firm Novo Nordisk, are in early talks for a minority stake, ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
